Literature DB >> 29749539

Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma.

Asuka Morikawa1, Tomoatsu Hayashi1, Mana Kobayashi1, Yuki Kato2, Katsuhiko Shirahige2, Takehiko Itoh3, Mitsuyoshi Urashima4, Aikou Okamoto5, Tetsu Akiyama1.   

Abstract

Ovarian clear cell carcinoma (OCCC) is a chemotherapy‑resistant epithelial ovarian cancer with poor prognosis. To identify genomic alterations involved in the development of OCCC, we analyzed somatic copy number alterations in OCCC using comparative genomic hybridization (CGH). Here we showed that the chromosomal regions 8p11.21, 8p11.22, 12p13.31 and 20q13.2 were amplified in OCCC. We also demonstrated that small segments in the chromosomal regions 3q26.1, 4q13.2 and 22q11.23 were deleted. Kaplan‑Meier survival analyses revealed that patients with amplification within 8p11.21 or a deletion within 3q26.1 had a shorter progression‑free survival (PFS) time than those without such alterations. In addition, patients with amplification in three of the four chromosomal regions 8p11.21, 8p11.22, 12p13.31 and 20q13.2 had shorter overall survival (OS). We also demonstrated that amplification of 12p13.3 or three of the four chromosomal regions 8p11.21, 8p11.22, 12p13.31 and 20q13.2, or a deletion in the chromosomal region 3q26.1 was associated with chemotherapy resistance. Our findings suggest that copy number alterations in 8p11.21‑22, 12p13.31, 20q13.2, 3q26.1, 4q13.2 and 22q11.23 are critical for the development and survival of OCCC.

Entities:  

Mesh:

Year:  2018        PMID: 29749539     DOI: 10.3892/or.2018.6419

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Combining targeted sequencing and ultra-low-pass whole-genome sequencing for accurate somatic copy number alteration detection.

Authors:  Junfeng Fu; Weihua Guo; Cheng Yan; Zhenyang Lv; Yu Wang; Ze Wang; Zhe Fan; Ting Lei
Journal:  Funct Integr Genomics       Date:  2021-02-04       Impact factor: 3.410

2.  Signatures of Discriminative Copy Number Aberrations in 31 Cancer Subtypes.

Authors:  Bo Gao; Michael Baudis
Journal:  Front Genet       Date:  2021-05-13       Impact factor: 4.599

3.  Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data.

Authors:  Ning Zhao; Maozu Guo; Kuanquan Wang; Chunlong Zhang; Xiaoyan Liu
Journal:  Front Bioeng Biotechnol       Date:  2020-04-02

4.  Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors.

Authors:  Keiko Saotome; Tatsuyuki Chiyoda; Eriko Aimono; Kohei Nakamura; Shigeki Tanishima; Sachio Nohara; Chihiro Okada; Hideyuki Hayashi; Yuka Kuroda; Hiroyuki Nomura; Nobuyuki Susumu; Takashi Iwata; Wataru Yamagami; Fumio Kataoka; Hiroshi Nishihara; Daisuke Aoki
Journal:  Cancer Med       Date:  2020-08-19       Impact factor: 4.452

5.  Clinical significance of PI3 and HLA-DOB as potential prognostic predicators for ovarian cancer.

Authors:  Yanrong Li; Haixia Li; Baojun Yang; Jing Wei; Cheng Zhen; Limin Feng
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

Review 6.  SALL Proteins; Common and Antagonistic Roles in Cancer.

Authors:  Claudia Álvarez; Aracelly Quiroz; Diego Benítez-Riquelme; Elizabeth Riffo; Ariel F Castro; Roxana Pincheira
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.